In this episode of Managed Care Cast, Ella Hohmann speaks with Douglas Marks, MD, breast medical oncologist and associate ...
Manufacturer-sponsored biologic coupons have decreased since 2018, with rising per-claim values, impacting patient costs and ...
Generic dapagliflozin is indicated to lower heart failure hospitalization risk in type 2 diabetes with established ...
JoAnn Manson, MD, shares findings from the VIVID trial on vitamin D, the timing of use, and its potential to reduce long ...
Across tumor types, 1-year NGS uptake rose substantially from 2018 to 2022, reaching 74.5% in aNSCLC and 78.1% in mCRC, but ...
Ectopic germinal centers (GCs) were found to be a prognostic factor for poor outcomes for patients with thymoma-associated ...
A new systematic review and meta-analysis appearing in the Journal of Sport and Health Science suggests that combining strength and aerobic exercise may offer greater improvements ...
With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it. One of the most pressing financial debates in ...
Two-year data confirm DOR/ISL delivers durable viral suppression—even in patients with high viral loads or advanced disease.
Reclassifying vaccines as shared clinical decision-making creates an additional financial risk. If ACIP no longer ...
Benjamin Lockshin, MD, FAAD, outlines the clinical and practical factors driving the dominance of IL-23 inhibitors in biologic initiation, highlighting their favorable safety profile, ease of patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results